Development and characterization of a fecal-induced peritonitis model of murine sepsis: results from a multi-laboratory study and iterative modification of experimental conditions.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sharma Neha, Chwastek Damian, Dwivedi Dhruva J, Schlechte Jared, Yu Ian-Ling, McDonald Braedon, Arora Jaskirat, Cani Erblin, Eng Mikaela, Engelberts Doreen, Kuhar Eva, Medeiros Sarah K, Bourque Stephane L, Cepinskas Gediminas, Gill Sean E, Jahandideh Forough, Macala Kimberly F, Panahi Sareh, Pape Cynthia, Sontag David, Sunohara-Neilson Janet, Fergusson Dean A, Fox-Robichaud Alison E, Liaw Patricia C, Lalu Manoj M, Mendelson Asher A, National Preclinical Sepsis Platform, Sepsis Canada
Аннотация
RESULTS: Escalating doses of fecal slurry (0.5-2.5 mg/g) resulted in increased disease severity, as assessed by the modified Murine Sepsis Score (MSS). However, the MSS was poorly associated with progression to death during the experiments, and mice were found dead without elevated MSS scores. Administration of early antibiotics within 4 h of inoculation rescued the animals from sepsis compared with late administration of antibiotics after 12 h, as evidenced by 100% survival and reduced bacterial load in peritoneum and blood in the early antibiotic group. Site 1 and site 2 had statistically significant differences in mortality (60% vs 88%; p < 0.05) for the same dose of fecal slurry (0.75 mg/g) and marked differences in body temperature between groups.
CONCLUSIONS: We demonstrate a systematic approach to optimizing a 72-h FIP model of murine sepsis for use in multi-laboratory studies. Alterations to experimental conditions, such as dose of fecal slurry and timing of antibiotics, have clear impact on outcomes. Differences in mortality between sites despite rigorous standardization warrants further investigations to better understand inter-laboratory variation and methodological design in preclinical studies.